deltatrials
Completed PHASE3 NCT03207750

This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

Immunogenicity, Reactogenicity and Safety Study of Pediarix®, Hiberix® and Prevenar 13® Co-administered With Two Different Formulations of GSK Biologicals' HRV Vaccine (444563) in Healthy Infants 6-12 Weeks of Age

Sponsor: GlaxoSmithKline

Conditions Rotavirus Infection Rotavirus Vaccines
Interventions Hiberix Pediarix Prevenar 13 Rotarix
Updated 13 times since 2017 Last updated: Dec 7, 2020 Started: Sep 14, 2017 Primary completion: Oct 9, 2018 Completion: Mar 1, 2019

This PHASE3 trial investigates Rotavirus Infection and Rotavirus Vaccines and is currently completed. GlaxoSmithKline leads this study, which shows 13 recorded versions since 2017 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Change History

13 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Nov 2019 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 8 earlier versions

  1. Jun 2019 — Nov 2019 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Nov 2018 — Jun 2019 [monthly]

    Active Not Recruiting PHASE3

  3. Jul 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  4. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  5. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  6. Jan 2018 — Mar 2018 [monthly]

    Recruiting PHASE3

  7. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  8. Aug 2017 — Dec 2017 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Altamonte Springs, United States, Bardstown, United States, Bingham Farms, United States, Birmingham, United States, Boone, United States, Boynton Beach, United States, Charleston, United States, Charlottesville, United States, Cleveland, United States, Colorado Springs, United States and 32 more location s